We just released the ninth installment in our AI Visibility Index research series, produced in editorial partnership with Haute MD. This one looks at the medical aesthetics category — a $22 billion global market that is now the fastest-shifting healthcare sub-category we track for AI citation behavior.
The findings are sharp. Botox, Juvéderm, CoolSculpting, SkinCeuticals, and Morpheus8 lead the index across neurotoxin, filler, body contouring, medical-grade skincare, and energy-device queries. The top 15 brands capture about 62% of AI citation share. But the more important story sits in what the index reveals about how patient discovery is being rebuilt in real time — and why the lessons extend well beyond aesthetics.
The Instagram Era Is Over
For the last decade, medical aesthetics was an Instagram-led category. Influencer content drove curiosity. Before-and-afters drove inquiry. Practitioner accounts drove bookings. That discovery funnel is not slowing down. It is collapsing.
Patients today are starting their research in ChatGPT, Perplexity, and Google AI Overviews before they open Instagram. What the AI surfaces in that first query shapes which brands and which providers even enter consideration. If your product is not cited in the answer, you are not in the consideration set. The social-media channel that built the category is still there, but it has been demoted from “discovery” to “confirmation” — a very different role in the buying funnel and a very different valuation for marketing spend.
That same pattern is now showing up in every consumer category I work in. Aesthetics is just early and visible.
GLP-1s Are Rewriting Demand Patterns Faster Than Marketing Teams Are Adapting
GLP-1 weight-loss medications are reshaping demand for body contouring, skin tightening, and facial volume restoration at a pace that outruns most brand planning cycles. Patients who lost 40 pounds on semaglutide are not looking for the same procedures the industry has spent 15 years marketing to them. AI citation patterns are already reflecting the shift. Brand content calendars, in most cases, are not.
The lesson generalizes. Any category that sits downstream of a pharma shift — metabolic health, cardiology, mental health, aging-related consumer goods — is facing the same compression. The AI layer is surfacing the new patient reality faster than the brand layer can update. Whoever closes that gap first wins the new demand curve.
Provider-First Editorial Is a Citation Weapon
Haute MD’s role in this index deserves specific attention. The network’s practitioner-feature model generates long-form, provider-bylined, procedure-specific content. AI models cite that content at rates general beauty publications cannot match. The cumulative effect across hundreds of featured dermatologists and plastic surgeons is a compounding citation network.
The strategic takeaway for any consumer brand sitting in a credentialed category — aesthetics, legal, financial services, health and wellness — is clear. Provider-bylined, expert-credentialed, procedure-specific editorial should be weighted two to three times higher than standard consumer-editorial coverage in your GEO strategy. If you are still paying the same rate for an Allure mention and a credentialed-practitioner long-form feature, you are miscounting the citation value of the second one by a significant multiple.
What Brands Should Actually Do
Three actions every medical aesthetics brand — and every brand in a clinically adjacent category — should take this quarter:
One, audit your AI citation share. If you do not know whether your brand appears in the top-three AI answers for your five most important category queries, you are flying blind on the discovery channel that now drives patient acquisition. This is not a measurement luxury. It is the minimum viable dashboard for 2026.
Two, re-weight your earned-media budget toward credentialed, provider-first, long-form editorial.Consumer editorial still matters. But it is now one input among several. Peer-reviewed clinical authority, FDA documentation, manufacturer clinical content hubs, and provider-bylined features are where LLMs are pulling the most weight.
Three, build for the new patient journey. GLP-1s, AI-first discovery, and the decline of social referral are not going to reverse. The patient in front of your practice or your sales team has started her research in a place your brand has not been optimized for. Fix the infrastructure that sits inside the AI answer, and the funnel beneath it re-aligns.
Why This Index Exists
We built the AI Visibility Index series to do one thing: make AI citation performance measurable, comparable, and actionable for brands that are trying to get serious about the discovery surface that is now running ahead of SEO and social. The medical aesthetics edition is the ninth category we have audited. It will not be the last. Additional coverage of this research is running at Everything-PR.
The full report, produced in partnership with Haute MD, is available at hauteliving.com/hautemd/insights/medical-aesthetics-ai-visibility-index-2026.
If you are running a consumer brand in 2026 and you have not measured your AI citation share, measure it. That is the first step. Everything else follows.
Ronn Torossian is the founder of 5WPR, one of the largest independent public relations and digital marketing agencies in the United States. 5WPR operates a dedicated GEO (Generative Engine Optimization) practice and a specialist Dermatology & Aesthetics marketing practice.
